Similarly, obeticholic acid (OCA), a highly selective FXR agonist, shows therapeutic potential for NASH by alleviating oxidative stress, reducing inflammation and preventing apoptosis. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.